{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:11:58Z","timestamp":1782951118780,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/j.ygyno.2008.02.009","type":"journal-article","created":{"date-parts":[[2008,4,19]],"date-time":"2008-04-19T09:17:43Z","timestamp":1208596663000},"page":"49-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":125,"title":["Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia"],"prefix":"10.1016","volume":"110","author":[{"given":"Halla S.","family":"Nimeiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Kasza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Faoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter M.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett E.","family":"Vokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gini F.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2008.02.009_bib1","first-page":"1105","article-title":"Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms","volume":"74","author":"Abu-Jawdeh","year":"1996","journal-title":"Lab Invest"},{"key":"10.1016\/j.ygyno.2008.02.009_bib2","first-page":"360","article-title":"Vascular endothelial growth factor serum concentrations in ovarian cancer","volume":"92","author":"Tempfer","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2008.02.009_bib3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/jnci\/90.6.447","article-title":"Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice","volume":"90","author":"Yoneda","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2008.02.009_bib4","first-page":"3193","article-title":"Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer","volume":"8","author":"Cooper","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2008.02.009_bib5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ygyno.2006.03.058","article-title":"Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer","volume":"103","author":"Hefler","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2008.02.009_bib6","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/bjc.1997.537","article-title":"Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels","volume":"76","author":"Yamamoto","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2008.02.009_bib7","first-page":"587","article-title":"The prognostic significance of angiogenesis in epithelial ovarian carcinoma","volume":"5","author":"Alvarez","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2008.02.009_bib8","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.02.009_bib9","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.02.009_bib10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/bjc.1996.53","article-title":"The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer","volume":"73","author":"Bartlett","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2008.02.009_bib11","first-page":"613","article-title":"EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients","volume":"17","author":"Fischer-Colbrie","year":"1997","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2008.02.009_bib12","doi-asserted-by":"crossref","first-page":"8637","DOI":"10.1158\/1078-0432.CCR-05-1436","article-title":"Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer","volume":"11","author":"Psyrri","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2008.02.009_bib13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00004347-199701000-00010","article-title":"Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors","volume":"16","author":"Niikura","year":"1997","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2008.02.009_bib14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00109-006-0054-4","article-title":"Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma","volume":"84","author":"Lassus","year":"2006","journal-title":"J Mol Med"},{"key":"10.1016\/j.ygyno.2008.02.009_bib15","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ijgc-00009577-200509000-00012","article-title":"Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1\/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study","volume":"15","author":"Gordon","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2008.02.009_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1541-7786.MCR-06-0404","article-title":"The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents","volume":"5","author":"Tabernero","year":"2007","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ygyno.2008.02.009_bib17","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1200\/JCO.2005.02.477","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.02.009_bib18","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1200\/JCO.2005.01.8234","article-title":"Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.02.009_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2008.02.009_bib20","doi-asserted-by":"crossref","first-page":"403s","DOI":"10.1200\/jco.2007.25.18_suppl.7576","article-title":"Epidermal growth factor receptor (EGFR) immunohistochemistry: comparison of antibodies (Abs) and cut points to predict benefit from gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer (NSCLC)","volume":"25","author":"Dziadziuszko","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.02.009_bib21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/ncponc0400","article-title":"Gefitinib response of erlotinib-refractory lung cancer involving meninges\u2014role of EGFR mutation","volume":"3","author":"Choong","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ygyno.2008.02.009_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.ygyno.2008.02.009_bib23","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-05-0462","article-title":"Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study","volume":"11","author":"Schilder","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2008.02.009_bib24","first-page":"1527","article-title":"Epidermal growth factor receptor (EGFR) mutation rate does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study","volume":"27","author":"Mustea","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ygyno.2008.02.009_bib25","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2007.11.5154","article-title":"Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer","volume":"25","author":"Bukowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.02.009_bib26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ygyno.2007.01.019","article-title":"A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study","volume":"105","author":"McMeekin","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2008.02.009_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2006.06.014","article-title":"The role of bevacizumab in ovarian cancer\u2014an evolving story","volume":"102","author":"Aghajanian","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2008.02.009_bib28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2008.02.009_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2007.01.038","article-title":"What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?","volume":"105","author":"Han","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2008.02.009_bib30","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2008.02.009_bib31","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1245\/s10434-006-9337-9","article-title":"Gastrointestinal perforation due to bevacizumab in colorectal cancer","volume":"14","author":"Saif","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ygyno.2008.02.009_bib32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ygyno.2007.06.004","article-title":"Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening","volume":"107","author":"Simpkins","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2008.02.009_bib33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2008.02.009_bib34","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2013carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2008.02.009_bib35","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2008.02.009_bib36","article-title":"Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced Mullerian tumors","volume":"vol. 24","author":"Penson","year":"2006","journal-title":"J Clin Oncol, ASCO Annual Meeting Proceedings"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825808001261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825808001261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:22:26Z","timestamp":1758770546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825808001261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S0090825808001261"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2008.02.009","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2008.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}